Immix Biopharma (IMMX) Price & Analysis

Compare

147 Followers

IMMX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.26 - $3.20

Previous Close$2.25

Volume74.23K

Average Volume (3M)213.30K

Market Cap

$79.45M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.55

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.72

Shares Outstanding27,877,293

10 Day Avg. Volume270,179

30 Day Avg. Volume213,301

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$7.00

Price Target Upside192.89% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsInterim NEXICART-2 trial data appeared encouraging, with a 100% response rate and a 70% hematologic complete response rate without observed relapses or progression.

Regulatory ProgressThe FDA granted RMAT designation to NXC-201, which is being evaluated in NEXICART-2 trial for the treatment of relapsed/refractory AL Amyloidosis.

Bears Say

Follow-up RequirementsThere is a need for longer-term follow-up for more clarity on the durability of the results from the NEXICART-2 trial due to the small sample size.

Market CompetitionNXC-201's clinical data compares favorably to those seen with prior agents, like Darzalex and CAEL-101.

Immix Biopharma News

Immix Biopharma announces ‘class-leading’ safety profile for NXC-201

Immix Biopharma (IMMX) announced a “class-leading” safety profile for sterically-optimized CAR-T NXC-201, including absence of neurotoxicity of any...

29d ago

IMMX

Immix Biopharma’s Strategic Expansion and Promising Trial Results Reinforce Buy Rating

Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, retaining the price target of...

1M ago

IMMX

Immix Biopharma announces accelerated NEXICART-2 trial progress

Immix Biopharma (IMMX) announced accelerated U.S. NEXICART-2 clinical trial progress in relapsed/refractory AL Amyloidosis. NEXICART-2 now includes 18...

1M ago

IMMX

Immix Biopharma Holds Annual Meeting, Elects Directors

Immix Biopharma ( ($IMMX) ) has issued an update. On June 20, 2025, Immix Biopharma, Inc. held its...

2M ago

IMMX

Promising Interim Results from NEXICART-2 Trial Support Buy Rating for NXC-201

Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma (IMMX – Research Report), with...

2M ago

IMMX

Immix Biopharma files $13.45M common stock ATM offering

Immix entered into an at the market offering agreement, or ATM agreement, with Citizens JMP Securities relating to...

2M ago

IMMX

Immix Biopharma Enters At The Market Offering Agreement

The latest announcement is out from Immix Biopharma ( ($IMMX) ). On June 3, 2025, Immix Biopharma, Inc....

2M ago

IMMX

Immix Biopharma announces NXC-201 trial met primary endpoint

Immix Biopharma (IMMX) announced meeting its primary endpoint of complete response rate for cell therapy NXC-201 at an...

2M ago

IMMX

Immix Biopharma expands U.S. clinical sites for NEXICART-2 trial

Immix Biopharma (IMMX) announced that 14 U.S. sites are actively enrolling in U.S. multi-site study NEXICART-2. This milestone...

3M ago

IMMX

Buy Rating for Immix Biopharma: Promising Clinical Advancements and Market Potential of NXC-201

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc....

6M ago

IMMX

Immix Biopharma receives FDA RMAT designation for NCX-201 in r/r AL Amyloidosis

Immix Biopharma (IMMX) announced that the U.S. FDA has granted RMAT designation to sterically-optimized CAR-T NXC-201 for the...

6M ago

IMMX

Immix Biopharma accelerates enrollment in U.S. AL amyloidosis trial of NXC-201

Immix Biopharma (IMMX) announced completion of the six-patient Phase 1b safety run-in segment in the U.S. NEXICART-2 study...

7M ago

IMMX

Immix Biopharma announces data from four patients in NEXICART-2 U.S. trial

Immix Biopharma (IMMX) announced initial clinical data from the first four patients in the ongoing NEXICART-2U.S. study of...

8M ago

IMMX

Immix Biopharma announces publication of NXC-201 clinical results

Immix Biopharma (IMMX) announced the Journal of Clinical Oncology published NXC-201 clinical results in relapsed/refractory AL Amyloidosis. The...

8M ago

IMMX

IMMX FAQ

What was Immix Biopharma, Inc.’s price range in the past 12 months?

Immix Biopharma, Inc. lowest stock price was $1.26 and its highest was $3.20 in the past 12 months.

What is Immix Biopharma, Inc.’s market cap?

Immix Biopharma, Inc.’s market cap is $79.45M.

When is Immix Biopharma, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Immix Biopharma, Inc.’s earnings last quarter?

Currently, no data Available

Is Immix Biopharma, Inc. overvalued?

According to Wall Street analysts Immix Biopharma, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Immix Biopharma, Inc. pay dividends?

Immix Biopharma, Inc. does not currently pay dividends.

What is Immix Biopharma, Inc.’s EPS estimate?

Immix Biopharma, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immix Biopharma, Inc. have?

Immix Biopharma, Inc. has 27,877,293 shares outstanding.

What happened to Immix Biopharma, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Immix Biopharma, Inc.?

Currently, no hedge funds are holding shares in IMMX

Immix Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-111.42%

Trailing 12-Months

Asset Growth

-42.09%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Immix Biopharma, Inc.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Immix Biopharma (IMMX) Earnings & Revenues

Currently, no data available

Please return soon. This page is being updated.

Historic Earnings Reports

IMMX Stock 12 Month Forecast

Average Price Target

$7.00

▲(192.89% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","2":"$2","4":"$4","6":"$6","8":"$8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2022","6":"Jul<br/>2024","9":"Jan<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.19,2.56,2.93,3.3,3.67,4.04,4.41,4.78,5.15,5.5200000000000005,5.890000000000001,6.26,6.630000000000001,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.19,2.56,2.93,3.3,3.67,4.04,4.41,4.78,5.15,5.5200000000000005,5.890000000000001,6.26,6.630000000000001,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.19,2.56,2.93,3.3,3.67,4.04,4.41,4.78,5.15,5.5200000000000005,5.890000000000001,6.26,6.630000000000001,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.6,"date":1656633600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.41,"date":1659312000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.85,"date":1661990400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.36,"date":1664582400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.36,"date":1664582400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.63,"date":1675209600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >